CVN424 Monotherapy for Early Parkinson's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.
Are You a Good Fit for This Trial?
This trial is for adults over 30 with early, untreated Parkinson's Disease who can walk (with or without help) and have mild to moderate disease severity. They shouldn't need Parkinson's medication during the study and must use reliable contraception if applicable. People with previous PD surgery, certain medical conditions, or recent use of specific drugs cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CVN424 150 mg or placebo for 12 weeks to evaluate effects on motor and non-motor functions in early Parkinson's Disease
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CVN424
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cerevance Beta, Inc.
Lead Sponsor